Retatrutide
Retatrutide is a compounded injectable that acts at three receptors, GLP-1, GIP and glucagon. Our partner pharmacy announced its final batch of retatrutide in August 2026, so availability is limited. Compounded medications are not FDA-approved.
Your path to Retatrutide
Complete the assessment
Answer a few questions about your weight history, metabolic health, and goals.
Provider review
A licensed provider decides whether this therapy fits you and sets your dose.
Care coordination
Your care team coordinates the prescription and dosing supplies after provider approval.
About this treatment
What it is
Retatrutide is a compounded injectable acting at three receptors rather than one or two. It is newer than semaglutide and tirzepatide and is not an FDA-approved product. Our partner pharmacy announced its final batch in August 2026, so ask your provider about supply before planning around it.
Who it's for
Patients whose provider decides a triple agonist fits, after reviewing their history, labs and current metabolic treatment. Because availability is limited, your provider will tell you what can actually be dispensed.
Forms we dispense
Injectable 16mg/mL (0.5mL · 1mL · 2mL)
A licensed provider reviews your history and requests labs when clinically appropriate before prescribing.
Prescriptions are coordinated with our licensed US pharmacy partner, with dosing supplies included when needed.
We do not sell pharmaceuticals online. Every prescription comes after a full provider review.
